Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice (Q40116397)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

0 references

Orthoebolavirus zairense

0 references

0 references

object named as

Jay Hooper

13

0 references

16

object named as

Gale Smith

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

author name string

Karin Lövgren Bengtsson

1

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Haifeng Song

2

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Linda Stertman

3

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Ye Liu

4

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

David C Flyer

5

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Michael J Massare

6

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Ren-Huan Xu

7

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Bin Zhou

8

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Hanxin Lu

9

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Steve A Kwilas

10

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Timothy J Hahn

11

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Eloi Kpamegan

12

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Ricardo Carrion

14

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Gregory Glenn

15

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

language of work or name

0 references

publication date

24 February 2016

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

1927-1935

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

A race for an Ebola vaccine: promises and obstacles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Ebola virus vaccines: an overview of current approaches

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

T-helper 1 cells elicited by H5N1 vaccination predict seroprotection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Matrix-M adjuvant: enhancing immune responses by 'setting the stage' for the antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Treatment of Ebola virus infection with antibodies from reconvalescent donors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Protective efficacy of neutralizing antibodies against Ebola virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Potential and emerging treatment options for Ebola virus disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Expanding roles for CD4⁺ T cells in immunity to viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Development of vaccines for prevention of Ebola virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Disease modeling for Ebola and Marburg viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

A hantavirus pulmonary syndrome (HPS) DNA vaccine delivered using a spring-powered jet injector elicits a potent neutralizing antibody response in rabbits and nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Properties of mouse and human IgG receptors and their contribution to disease models

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

IgG subclasses and allotypes: from structure to effector functions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Epitopes involved in antibody-mediated protection from Ebola virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

The role of germinal centers for antiviral B cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Modulation of SAP dependent T:B cell interactions as a strategy to improve vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Follicular T-helper cells: controlled localization and cellular interactions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

T follicular helper cell differentiation, function, and roles in disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.033

7 January 2021

Identifiers

10.1016/J.VACCINE.2016.02.033

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40116397&oldid=1885738022"